Precision Fermentation Platform for Sustainable Protein
An engineered mycoprotein yeast strain redirected from four Indian VC passes to Singapore and EU sector specialists, closing a seed round in six weeks and a reworked EU Horizon grant.
- Origin
- Joint initiative between an IIT biotechnology department and a food science research group
- Founded
- 2021
- Core Innovation
- Engineered yeast strain producing high-purity mycoprotein at 40% lower production cost, 70% lower land use, and 80% lower water use than animal-derived whey.
- Capital Outcome
- ₹11.80 Crore total: ₹3.20 Crore EU Horizon Europe grant and ₹8.60 Crore Series Seed from a Singapore-based sustainable food fund
Diagnostic findings at engagement
- Four Indian venture capital pitches had each resulted in a pass, with reasons cited as regulatory risk associated with novel food approval and consumer adoption risk given limited Indian familiarity with precision fermentation products.
- An initial EU Horizon Europe application had been rejected because it was not structured as a qualifying EU-India joint research collaboration, a procedural requirement for non-EU-led applications.
- The existing financial model addressed only production volume, with no revenue model, customer segmentation, or pricing structure defined.
- Competitive landscape materials referenced only Indian market players, omitting the broader global alternative protein investment context in which the company's relevant comparables and potential investors were actually situated.
Service interventions applied
Investor Geography Reorientation
Redirected venture targeting from Indian generalist funds, which had consistently passed on regulatory and adoption risk, to Singapore and European alternative-protein-focused funds with established sector risk appetite. A first qualified investor meeting was secured within six weeks of redirection.
Grant Narrative: EU Horizon Reapplication
Restructured the application as a formal EU-India joint project, identifying a leading European food science university as the EU-based academic partner, satisfying Horizon's international collaboration eligibility requirement under the Cluster 6 Food Systems topic.
Regulatory Strategy
Mapped a dual-track regulatory pathway (FSSAI Novel Food Product approval in India and EFSA Novel Food pre-submission in the EU) and identified the Singapore Food Agency as the fastest available regulatory jurisdiction for first commercial launch, recommending a sequenced market entry beginning in Singapore.
Venture Pitch and Financial Model
Rebuilt the pitch narrative around a documented permanent cost-of-goods advantage relative to United States and European competitors and a completed EFSA pre-submission status. Constructed a financial model projecting ₹18 Crore in revenue within 36 months from B2B ingredient sales.
Go-to-Market Strategy
Rejected a direct-to-consumer launch route in favour of a B2B ingredient supply model targeting functional food categories including sports nutrition, infant formula, and clinical nutrition, removing the consumer behaviour change risk previously cited by Indian investors.
Founder Derisking
Identified a single-founder key-person dependency, as the lead scientist was the sole inventor and sole technical understander of the yeast engineering process. Recruited a second PhD-level bioprocess engineer as co-founder under a vesting structure, resolving a key-person risk previously cited by two prospective investors as a pass reason.
Position at engagement vs. position at close
Swipe the table sideways to compare.
| Dimension | At engagement | At close |
|---|---|---|
| Investor Geography | India-only; four passes on regulatory risk | Singapore and EU funds; first meeting in six weeks |
| Go-to-Market Model | Direct-to-consumer | B2B ingredient supply to functional food categories |
| Key-Person Risk | Single founder, sole IP holder | Second co-founder added; knowledge transfer documented |
| Capital Secured | ₹0 | ₹11.80 Crore |